EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMetaanalyseOpen Access · CC BY-NC 4.0

Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials

Jiaxi Liu, Huan Zhai, Liqi Shang, Peng Wang, Jiaxuan Liu, Luke Wang, Qiwen You, Meiwen Qin, Yanan Ma, Haibo Shao

Liver Cancer · 30.04.2026 · 1-20

DOI: 10.1159/000552229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver Cancer, online erschienen am 30.04.2026. Verfasst von Jiaxi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Transarterial chemoembolization (TACE) is the standard treatment for unresectable, nonmetastatic hepatocellular carcinoma (HCC). Although adding systemic therapies (TACE + S) is hypothesized to mitigate TACE-induced angiogenesis and enhance efficacy, the definitive clinical advantage of TACE + S over TACE monotherapy, particularly with respect to overall survival (OS), remains uncertain. We aimed to comprehensively evaluate the efficacy and safety of this combination using a rigorous meta-analysis and trial sequential analysis (TSA).

Methods

We systematically searched major databases for randomized controlled trials (RCTs) comparing TACE + S versus TACE alone or TACE plus placebo in patients with unresectable HCC without macrovascular invasion or extrahepatic metastasis. The primary outcome was OS; secondary outcomes included progression-free survival, time to progression (TTP), objective response rate (ORR), and adverse events (AEs). TSA was employed to assess the statistical reliability of findings and the adequacy of the cumulative evidence across all outcomes.

Results

A total of 10 RCTs comprising 2,296 patients were included. Compared with TACE alone/placebo, TACE + S demonstrated a statistically significant improvement in OS (hazard ratio [HR] = 0.83, 95% CI: 0.73–0.95, p = 0.008), with TSA confirming the statistical reliability of the evidence. TACE + S also significantly improved TTP based on mRECIST (HR = 0.63, 95% CI: 0.54–0.74, p < 0.001) and ORR by RECIST 1.1 (relative risk = 1.44, 95% CI: 1.22–1.70, p < 0.001). Subgroup analysis showed a more pronounced OS benefit in patients with HBV-related HCC (HR = 0.69, p = 0.009). However, the combination strategy was associated with a significantly higher incidence of both all-grade and grade ≥3 treatment-related AEs, though no treatment-related deaths were reported.

Conclusion

In patients with unresectable, nonmetastatic HCC, the combination of TACE and systemic therapy provides superior OS, more favorable tumor control, and delayed disease progression compared with TACE monotherapy. These significant benefits are particularly pronounced in the HBV-associated HCC population. While the increased risk of AEs is notable, this approach remains a viable option, underscoring the necessity for careful patient selection and proactive management strategies.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaMeta-analysisNonmetastatic hepatocellular carcinomaTransarterial chemoembolizationTrial sequential analysis

Autor:innen und Institutionen

  • Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, China.
  • Key Laboratory of Environmental Stress and Chronic Disease Control and Prevention, Ministry of Education, China Medical University, Shenyang, China.
  • Department of Biostatistics and Epidemiology, School of Public Health, China Medical University, Shenyang, China.
  • Health Sciences Institute, China Medical University, Shenyang, China.
  • Liaoning Key Laboratory of Obesity and Glucose/Lipid Associated Metabolic Diseases, China Medical University, Shenyang, China.

Zitieren

APA

Liu, J., Zhai, H., Shang, L., Wang, P., Liu, J., Wang, L., You, Q., Qin, M., Ma, Y., & Shao, H. (2026). Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials. Liver Cancer, 1-20. https://doi.org/10.1159/000552229

Vancouver

Liu J, Zhai H, Shang L, Wang P, Liu J, Wang L, et al. Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials. Liver Cancer. 2026:1-20. doi:10.1159/000552229

BibTeX
@article{Liu2026,
  author = {Liu, Jiaxi and Zhai, Huan and Shang, Liqi and Wang, Peng and Liu, Jiaxuan and Wang, Luke and You, Qiwen and Qin, Meiwen and Ma, Yanan and Shao, Haibo},
  title = {Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials},
  journal = {Liver Cancer},
  year = {2026},
  pages = {1--20},
  doi = {10.1159/000552229}
}
Kostenlos starten →